Table 1.
Baseline characteristics of the study participants, n (%)
| Characteristic | n (%) |
| Age (SD) | 35.6 (9.4) |
| Male | 8 (81.8) |
| Female | 3 (18.2) |
| Age at diagnosis (Montreal classification) | |
| A1 (age < 16 yr) | 1 (9.1) |
| A2 (age 17-40 yr) | 9 (81.8) |
| A3 (age > 40 yr) | 1 (9.1) |
| Location (Montreal classification) | |
| L1 (terminal ileum disease) | 5 (45.5) |
| L2 (colonic disease) | 3 (27.3) |
| L3 (ileocolonic disease) | 3 (27.3) |
| L4 (upper GI) | 0 (0.0) |
| Behavior (Montreal classification) | |
| B1 (inflammatory) | 3 (27.3) |
| B2 (stricturing) | 4 (36.4) |
| B3 (penetrating) | 2 (18.2) |
| B2 + B3 | 2 (18.2) |
| Perianal disease | 4 (36.4) |
| Duration of disease, mean (SD), yr | 8.8 (6.9) |
| Medication at the time of WMT | |
| None | 2 (18.2) |
| Mesalamines | 7 (63.6) |
| Steroids | 1 (9.1) |
| Immunomodulators | 3 (27.3) |
| Biologics therapy | 1 (9.1) |
| Bowel surgery | 2 (18.2) |
| Anal surgery | 4 (36.4) |
| Smoking status | |
| Current | 0 (0.0) |
| Ex-smoker | 2 (18.2) |
| Never smoker | 9 (81.8) |
| Disease severity | |
| Mild | 11 (100.0) |
| Moderate | 0 (0.0) |
| Severe | 0 (0.0) |
| Route of WMT | |
| Mid-gut TET | 4 (36.4) |
| Colonic TET | 7 (63.6) |
GI: Gastrointestinal; WMT: Washed microbiota transplantation; TET: Transendoscopic enteral tubing.